<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cystic fibrosis: Genetics and pathogenesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cystic fibrosis: Genetics and pathogenesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cystic fibrosis: Genetics and pathogenesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julie P Katkin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George B Mallory, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cystic fibrosis (CF) is a multisystem disease affecting the lungs, digestive system, sweat glands, and reproductive tract. The primary abnormality is in transport of chloride and sodium across secretory epithelia, resulting in thickened, viscous secretions in the bronchi, biliary tract, pancreas, intestines, and reproductive system [
         <a href="#rid1">
          1,2
         </a>
         ]. Although the disease is systemic, progressive lung disease continues to be the major cause of morbidity and mortality for most patients. Over a highly variable time course ranging from months to decades after birth, individuals eventually develop chronic infection of the respiratory tract with a characteristic array of bacterial flora, leading to progressive respiratory insufficiency and eventual respiratory failure [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The genetics and pathogenesis of CF are discussed here. CF-associated lung disease is discussed in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">
          "Cystic fibrosis: Management of advanced lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The diagnosis and pathophysiology of CF and its manifestations in other organ systems are also discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14544.html" rel="external">
          "Cystic fibrosis-related diabetes mellitus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">
          "Cystic fibrosis: Assessment and management of pancreatic insufficiency"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">
          "Cystic fibrosis: Hepatobiliary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CF is caused by pathogenic mutations in a single large gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein [
         <a href="#rid4">
          4-9
         </a>
         ]. Clinical disease generally requires pathogenic mutations in both copies of the
         <em>
          CFTR
         </em>
         gene, but individuals with a single pathogenic variant (carrier status) occasionally develop disease limited to one organ system, known as CFTR-related disorder. (See
         <a class="local">
          'CFTR-related disorder'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          The normal CFTR gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFTR belongs to the ABC (
         <strong>
          A
         </strong>
         TP-
         <strong>
          b
         </strong>
         inding
         <strong>
          c
         </strong>
         assette) family of proteins, a large group of related proteins that share transmembrane transport functions. ABC proteins include bacterial transporters for amino acids and other nutrients, surfactant transport proteins, and the mammalian multidrug-resistant (MDR) protein (or P-glycoprotein).
        </p>
        <p>
         CFTR functions as a regulated chloride channel, which, in turn, may regulate the activity of other chloride and sodium channels at the cell surface [
         <a href="#rid10">
          10-13
         </a>
         ]. The
         <em>
          CFTR
         </em>
         gene spans 250 kilobases on chromosome 7, encoding 1480 amino acids in the mature protein  (
         <a class="graphic graphic_figure graphicRef60265" href="/z/d/graphic/60265.html" rel="external">
          figure 1
         </a>
         ). The protein has two groups of six membrane-spanning regions, two intracellular nucleotide-binding folds (NBFs), and a highly charged "R domain" containing multiple phosphorylation sites. Activation of the chloride channel requires phosphokinase A-mediated phosphorylation of the R domain and the continuous presence of ATP in the NBFs [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Genetic changes in CFTR
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phenotypic expression of disease varies widely, primarily as a function of the specific mutation (or mutations) present [
         <a href="#rid16">
          16-21
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cftr2.org%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLKIA%2ByxmKEDSneo%2Fntc0llc%3D&amp;TOPIC_ID=6368" target="_blank">
          CFTR2 database
         </a>
         lists more than 2000 different mutations in the
         <em>
          CFTR
         </em>
         gene with potential to cause disease.
        </p>
        <p>
         The most common pathogenic mutation is F508del (also noted as delta F508, delF508, p.Phe508del, or c.1521_1523delCTT, all of which describe the deletion of three DNA bases coding for the 508
         <sup>
          th
         </sup>
         amino acid residue phenylalanine). At least one copy of this mutation is found in approximately 90 percent of CF patients, and 50 percent are homozygotes [
         <a href="#rid22">
          22
         </a>
         ]. Certain mutations are found at higher frequency in some ethnic groups because of apparent founder effects. As an example, five mutations account for an estimated 97 percent of CF alleles in the Ashkenazi Jewish population [
         <a href="#rid23">
          23
         </a>
         ]. A subset of the most frequent
         <em>
          CFTR
         </em>
         mutations is used for initial screening since the majority of individual mutations are very rare  (
         <a class="graphic graphic_table graphicRef65637" href="/z/d/graphic/65637.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Molecular diagnosis'
         </a>
         .)
        </p>
        <p>
         Mutations of the
         <em>
          CFTR
         </em>
         gene have been divided into five different classes as depicted in the figures  (
         <a class="graphic graphic_figure graphicRef80517" href="/z/d/graphic/80517.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef134588" href="/z/d/graphic/134588.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid2">
          2,25-27
         </a>
         ]. In general, mutations in classes I to III cause more severe disease than those in classes IV and V [
         <a href="#rid19">
          19,27
         </a>
         ]. However, the clinical implications of a specific combination of mutations vary, likely because of the influence of gene modifiers and other elements of the protein network that mediates CFTR folding, trafficking, and function; this network is sometimes termed the CFTR "functional landscape" [
         <a href="#rid28">
          28
         </a>
         ]. Genotype-phenotype correlations are weak for pulmonary disease in CF and somewhat stronger for the pancreatic insufficiency phenotype. (See
         <a class="local">
          'Gene modifiers'
         </a>
         below.)
        </p>
        <p>
         In most cases, specific mutations should not be used to make assumptions about the severity of disease in an individual patient. Knowledge of the mutations may be useful to guide initial therapy, but clinical decisions should be guided by observable parameters of growth, lung function, and nutritional status. Some new therapies are directed at specific classes of
         <em>
          CFTR
         </em>
         mutation.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Class I mutations: Defective protein production
         </span>
         <span class="headingEndMark">
          —
         </span>
         This type of defect is usually caused by nonsense, frameshift, or splice-site mutations, leading to premature termination of the messenger RNA (mRNA) and complete absence of CFTR protein. Examples include G542X, W1282X, R553X, 621+G&gt;T, and 1717-1G&gt;A [
         <a href="#rid27">
          27,29
         </a>
         ]. This type of mutation is present in approximately 20 percent of patients with CF  (
         <a class="graphic graphic_figure graphicRef134588" href="/z/d/graphic/134588.html" rel="external">
          figure 3
         </a>
         ). In some genetically homogenous populations, the percentage may be much higher [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Class II mutations: Defective protein processing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Class II mutations in the
         <em>
          CFTR
         </em>
         sequence cause abnormal post-translational processing of the CFTR protein, which prevents the protein from trafficking to the correct cellular location  (
         <a class="graphic graphic_figure graphicRef134588" href="/z/d/graphic/134588.html" rel="external">
          figure 3
         </a>
         ). This category includes the F508del (c.1521_1523delCTT) mutation. Approximately 50 percent of CF patients are homozygous for this mutation, and 90 percent will carry at least one copy [
         <a href="#rid27">
          27
         </a>
         ]. N1303Lys (N1303K) and A455E are also class II mutations; the latter is associated with relatively mild lung disease and pancreatic sufficiency. Newly developed modulators of CFTR (eg, the triple drug combination
         <a class="drug drug_general" data-topicid="122968" href="/z/d/drug information/122968.html" rel="external">
          elexacaftor-tezacaftor-ivacaftor
         </a>
         ) function in part by causing the cell to send the defective CFTR protein to the cell surface, where it may have some degree of function. (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Class III mutations: Defective regulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Class III mutations, also known as gating mutations, lead to diminished channel activity in response to ATP. Many involve alterations of the NBF regions, NBO1 and NBO2, which may retain varying degrees of sensitivity to nucleotide binding  (
         <a class="graphic graphic_figure graphicRef80517" href="/z/d/graphic/80517.html" rel="external">
          figure 2
         </a>
         ). Other
         <em>
          CFTR
         </em>
         mutations, mapped to the R domain, may also fall into this category. G551D is the most common class III mutation in White populations [
         <a href="#rid27">
          27
         </a>
         ].
         <a class="drug drug_general" data-topicid="17144" href="/z/d/drug information/17144.html" rel="external">
          Ivacaftor
         </a>
         , a modulator of CFTR function, improves CFTR function in patients with gating defects by allowing constitutive (ie, unmodulated) opening of the CFTR channel; these and other mutations that are responsive to ivacaftor are included in the table  (
         <a class="graphic graphic_table graphicRef130494" href="/z/d/graphic/130494.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators", section on 'Ivacaftor monotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Class IV mutations: Defective conduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         With class IV mutations, the protein is produced and correctly localized to the cell surface. However, although chloride currents are generated in response to cAMP stimulation, the rate of ion flow and the duration of channel opening are reduced when compared with normal
         <em>
          CFTR
         </em>
         function. R117H is the most common class IV mutation in White populations [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Class V mutations: Reduced amounts of functional CFTR protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         This class of mutation is not included in some schemes. It includes mutations that alter the stability of mRNA and others that alter the stability of the mature CFTR protein (the latter is sometimes classified separately into a class VI) [
         <a href="#rid31">
          31,32
         </a>
         ]. The mutation A455E has been classified as class II [
         <a href="#rid29">
          29
         </a>
         ] or class V [
         <a href="#rid19">
          19,33,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          GENE MODIFIERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The inconsistent association between CF genotypes and phenotypes points to a role for gene modifiers. These genetic variations are not directly related to the
         <em>
          CFTR
         </em>
         gene (cystic fibrosis transmembrane conductance regulator) but affect the severity or clinical manifestations of disease. Research into a variety of candidate genes is ongoing. There is good evidence that the following genes act as modifiers in CF and that approximately 20 percent of patients with classic CF carry mutations in one or both of these genes that exacerbates the pulmonary disease [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transforming growth factor-beta 1 (TGF-beta 1)
         </strong>
         – TGF-beta is a potent suppressor of T cell activation and can decrease T cell proliferation and cytokine production. In a study of 808 patients who were homozygous for the F508del mutation, polymorphisms in the TGF-beta 1 gene were associated with more severe CF lung disease [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">
          "The adaptive cellular immune response: T cells and cytokines", section on 'Role of cytokines in negative feedback'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">
          "The adaptive cellular immune response: T cells and cytokines", section on 'Treg'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mannose-binding lectin (MBL)
         </strong>
         – MBL is an important component of the complement system, and deficiencies in this protein increase the risk for pyogenic infections. In individuals with CF, variant MBL alleles are associated with reduced lung function, increased risk for chronic
         <em>
          Pseudomonas aeruginosa
         </em>
         and
         <em>
          Burkholderia
         </em>
         <em>
          cepacia
         </em>
         complex infections, and early death [
         <a href="#rid37">
          37
         </a>
         ]. In young patients with CF and pancreatic insufficiency, lower MBL-2 protein levels were associated with a steeper rate of decline in lung function and earlier age at first infection with
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid35">
          35
         </a>
         ]. These effects were exaggerated in individuals who also carried the TGF-beta 1 variant described above. (See
         <a class="medical medical_review" href="/z/d/html/3962.html" rel="external">
          "Inherited disorders of the complement system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          INCOMPLETE PHENOTYPE
         </span>
        </p>
        <p class="headingAnchor" id="H2068755213">
         <span class="h2">
          CFTR-related disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         A cystic fibrosis transmembrane conductance regulator (CFTR)-related disorder is defined as clinical disease limited to only one organ system associated with some evidence of CFTR dysfunction that does not meet full genetic or functional criteria for a CF diagnosis. Clinical manifestations may include isolated obstructive azoospermia, chronic rhinosinusitis, chronic pancreatitis, or pulmonary disease in adulthood [
         <a href="#rid38">
          38,39
         </a>
         ]. The pathogenetic mechanism responsible for clinical disease without two
         <em>
          CFTR
         </em>
         gene mutations is unclear, but other genetic or environmental factors likely contribute to the risk in some cases. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'CFTR-related disorder'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4022409737">
         <span class="h2">
          CFTR-related metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFTR-related metabolic syndrome (CRMS) is a term that describes infants and children with an equivocal diagnosis following newborn screening for CF and is found in 3 to 4 percent of infants with a positive newborn screen  (
         <a class="graphic graphic_table graphicRef117801" href="/z/d/graphic/117801.html" rel="external">
          table 3
         </a>
         ). The term "CF screen positive, inconclusive diagnosis" (CFSPID) is equivalent and is used in Europe. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'CRMS/CFSPID'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DISEASE PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of the organ dysfunction seen in CF has been studied in humans and cystic fibrosis transmembrane conductance regulator (CFTR)-knockout mice but remains incompletely understood [
         <a href="#rid40">
          40,41
         </a>
         ]. It appears that the physical and chemical abnormalities of CF airway secretions result in chronic infection with phenotypically unique bacteria, particularly
         <em>
          Pseudomonas
         </em>
         species. Other genetic factors, including polymorphisms of the tumor necrosis factor alpha (TNF-alpha) gene, may increase susceptibility to
         <em>
          P. aeruginosa
         </em>
         infection and contribute to the clinical manifestations of CF [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Primary abnormalities in fatty acid metabolism have been noted in biopsies of
         <em>
          CFTR
         </em>
         -expressing tissue from patients with CF [
         <a href="#rid43">
          43
         </a>
         ]. These changes, which result in increased tissue levels of arachidonic acid, also are present in the mouse model of CF but are not seen in tissue from patients with inflammatory bowel disease. Thus, increased tissue expression of arachidonic acid and its metabolites may contribute to the abnormal inflammation characteristic of CF.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Abnormal secretions
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFTR malfunction in the respiratory epithelium is associated with a variety of changes in electrolyte and water transport. The mechanisms involved and ultimate electrolyte composition of airway surface fluid in CF airways is a subject of ongoing research [
         <a href="#rid11">
          11-13,44-47
         </a>
         ]. The net result of these changes is an alteration in the rheology of airway secretions, which become thick and difficult to clear [
         <a href="#rid48">
          48
         </a>
         ]. An associated finding is an increased concentration of chloride in sweat secretions, which constitutes one of the methods of diagnosis of CF. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Gastrointestinal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thickened secretions caused by CFTR malfunction cause the gastrointestinal complications of CF. Impaired flow of bile and pancreatic secretions cause maldigestion and malabsorption, as well as progressive liver and pancreatic disease, leading to CF-related diabetes. Because of thickened intestinal secretions and maldigestion, CF patients are prone to intestinal obstruction (distal intestinal obstruction syndrome or intussusception) and to rectal prolapse. (See
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Chronic lung infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The chronic airway obstruction caused by viscous secretions is followed by progressive pulmonary colonization with pathogenic bacteria, including
         <em>
          Haemophilus
         </em>
         <em>
          influenzae
         </em>
         ,
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         , and eventually
         <em>
          P. aeruginosa
         </em>
         and/or
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         complex bacteria. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Progression of pulmonary disease'
         </a>
         .)
        </p>
        <p>
         Once infection is established, neutrophils are unable to control the bacteria, even though there is massive infiltration of these inflammatory cells into the lung tissue [
         <a href="#rid49">
          49
         </a>
         ]. Recruited neutrophils subsequently release elastase, which overwhelms the antiproteases of the lung and contributes to tissue destruction in a process known as "prolonged endobronchial protease activity" [
         <a href="#rid50">
          50
         </a>
         ]. In addition, large amounts of DNA and cytosol matrix proteins are released by degranulating neutrophils, contributing to the increased viscosity of the airway mucus [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Inflammation has been noted prior to the development of bacterial colonization and may be triggered by viral infections [
         <a href="#rid52">
          52
         </a>
         ]. In turn, chronic infection appears to be the major stimulus for an exuberant but ultimately ineffective inflammatory response that subsequently results in bronchiectasis [
         <a href="#rid53">
          53,54
         </a>
         ]. The inflammatory response itself appears to contribute to the progression of pulmonary dysfunction; this mechanism is the basis for the use of some antiinflammatory agents in treating CF lung disease [
         <a href="#rid55">
          55,56
         </a>
         ].
        </p>
        <p>
         Individuals with CF are particularly prone to chronic infection with
         <em>
          P. aeruginosa
         </em>
         , due in part to increased oxygen utilization by epithelial cells, which results in an abnormally decreased oxygen tension within the hyperviscous mucous layer  (
         <a class="graphic graphic_figure graphicRef51872" href="/z/d/graphic/51872.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid57">
          57
         </a>
         ]. This local hypoxia induces the characteristic phenotypic changes in
         <em>
          P. aeruginosa
         </em>
         (and some other gram-negative bacteria), including alginate production and loss of motility. This phenotype is consistent with the development of bacterial macrocolonies (or "biofilms") within the hypoxic regions of the airway mucus layer. Once this occurs, eradication of the organism is almost impossible. (See
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection", section on 'Persistence of the organism in the airways'
         </a>
         .)
        </p>
        <p>
         The frequent colonization and persistent infection caused by
         <em>
          P. aeruginosa
         </em>
         in CF patients is also related to the defective CFTR protein itself [
         <a href="#rid49">
          49
         </a>
         ]. Normal CFTR protein serves as the receptor for binding of
         <em>
          P. aeruginosa
         </em>
         lipopolysaccharide in vitro and extracts lipopolysaccharide from the surface of the organism for endocytosis into epithelial cells [
         <a href="#rid45">
          45,58,59
         </a>
         ]. This results in increased intranuclear translocation of the nuclear transcription factor NF kappa B and subsequent immunoactivation [
         <a href="#rid58">
          58-60
         </a>
         ]. This process does
         <strong>
          not
         </strong>
         occur in the presence of abnormal CFTR or in CFTR-knockout mice [
         <a href="#rid60">
          60
         </a>
         ], which may partially explain the inability of CF patients to control these infections. Disease-modifier genes appear to further affect the predisposition to
         <em>
          P. aeruginosa
         </em>
         infection, as described above. (See
         <a class="local">
          'Gene modifiers'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H877895282">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109226.html" rel="external">
          "Society guideline links: Cystic fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic basis of cystic fibrosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cystic fibrosis (CF) is caused by mutations in a single large gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical disease requires disease-causing mutations in both copies of the
         <em>
          CFTR
         </em>
         gene. The phenotypic expression of disease varies widely, as a function of the specific mutations present and the presence of gene modifiers. (See
         <a class="local">
          'Genetic changes in CFTR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CFTR mutation classes
         </strong>
         – Mutations of the
         <em>
          CFTR
         </em>
         gene have been divided into five different classes, depicted in the figures  (
         <a class="graphic graphic_figure graphicRef80517" href="/z/d/graphic/80517.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef134588" href="/z/d/graphic/134588.html" rel="external">
          figure 3
         </a>
         ). In general, mutations in classes I to III cause more severe disease than those in classes IV and V. However, the clinical implications of a specific combination of mutations are often unclear and specific mutations should not be used to make assumptions about the severity of disease in an individual patient. (See
         <a class="local">
          'Genetic changes in CFTR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common CFTR mutations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A subset of the most frequent
         <em>
          CFTR
         </em>
         mutations is recommended for initial testing since the majority of individual mutations are very rare  (
         <a class="graphic graphic_table graphicRef65637" href="/z/d/graphic/65637.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Genetic changes in CFTR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most common mutation is F508del (also noted as delta F508 or c.1521_1523delCTT, referring to deletion of three DNA bases coding for the 508
         <sup>
          th
         </sup>
         amino acid residue phenylalanine), which is found in approximately 70 percent of White patients with CF in the United States. (See
         <a class="local">
          'Class II mutations: Defective protein processing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gene modifiers
         </strong>
         – Gene modifiers are genetic variations that are not directly related to the
         <em>
          CFTR
         </em>
         gene but which nonetheless affect the severity or clinical manifestations of disease. Transforming growth factor-beta (TGF-beta) and mannose-binding lectin (MBL) are important gene modifiers in CF, and approximately 20 percent of CF patients carry variants in one or both of these genes that may exacerbate the pulmonary disease. (See
         <a class="local">
          'Gene modifiers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease pathogenesis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CFTR malfunction is associated with low water content in secretions from the respiratory, pancreatic, and biliary epithelium, which causes the secretions to be viscous and difficult to clear. (See
         <a class="local">
          'Abnormal secretions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the gastrointestinal tract, the abnormal bile and pancreatic secretions cause maldigestion and malabsorption, progressive liver and pancreatic disease, rectal prolapse, and intestinal obstruction (distal intestinal obstruction syndrome or intussusception). (See
         <a class="local">
          'Gastrointestinal effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the lung, the abnormal secretions cause chronic airway obstruction and reduce bactericidal killing, leading to progressive pulmonary colonization with pathogenic bacteria and to the formation of bacterial biofilms. Chronic infection causes an inflammatory response and tissue destruction, causing bronchiectasis. Infection with
         <em>
          Pseudomonas aeruginosa
         </em>
         is particularly favored in patients with CF due to abnormally decreased oxygen tension within the hyperviscous mucous layer. (See
         <a class="local">
          'Chronic lung infection'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratjen F, Döring G. Cystic fibrosis. Lancet 2003; 361:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drumm ML, Collins FS. Molecular biology of cystic fibrosis. Mol Genet Med 1993; 3:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992; 68:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guggino WB, Banks-Schlegel SP. Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 2004; 170:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995; 95:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman MJ, Yang Y, Wilson JM. Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat Genet 1995; 9:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson MP, Berger HA, Rich DP, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991; 67:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rich DP, Gregory RJ, Anderson MP, et al. Effect of deleting the R domain on CFTR-generated chloride channels. Science 1991; 253:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000; 84:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993; 329:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decaestecker K, Decaestecker E, Castellani C, et al. Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients. Eur Respir J 2004; 23:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992; 51:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerem E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatr Pulmonol 2005; 40:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 2015; 16:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moskowitz SM, Chmiel JF, Sternen DL, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 2008; 10:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amaral MD, Hutt DM, Tomati V, et al. CFTR processing, trafficking and interactions. J Cyst Fibros 2020; 19 Suppl 1:S33.
          </a>
         </li>
         <li class="breakAll">
          Ong T, Marshall SG, Karczeski BA et al. Cystic Fibrosis and Congenital Absence of the Vas Deferens (GeneReviews monograph). Available at: https://www.ncbi.nlm.nih.gov/books/NBK1250/ (Accessed on January 08, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukacs GL, Durie PR. Pharmacologic approaches to correcting the basic defect in cystic fibrosis. N Engl J Med 2003; 349:1401.
          </a>
         </li>
         <li class="breakAll">
          Fanen P, Hasnain A. Cystic fibrosis and teh CFTR gene. Atlas of Genetic and Cytogenetic Oncology and Hematology, 2001. Available at: http://documents.irevues.inist.fr/bitstream/handle/2042/37827/09-2001-CistFibID30032EL.pdf?sequence=3 (Accessed on February 08, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antunovic SS, Lukac M, Vujovic D. Longitudinal cystic fibrosis care. Clin Pharmacol Ther 2013; 93:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996; 22:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001; 31:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çolak Y, Nordestgaard BG, Afzal S. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003; 9:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent G, Iles R, Bear CE, et al. Lung disease in mice with cystic fibrosis. J Clin Invest 1997; 100:3060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosselin D, Stevenson MM, Cowley EA, et al. Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998; 157:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yarden J, Radojkovic D, De Boeck K, et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005; 60:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ernst RK, Yi EC, Guo L, et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999; 286:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest 2007; 132:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guggino WB. Cystic fibrosis and the salt controversy. Cell 1999; 96:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008; 32:783.
          </a>
         </li>
         <li class="breakAll">
          Davis PB. Pathophysiology of the lung disease in cystic fibrosis. In: Cystic Fibrosis, Davis PB (Ed), Marcel Dekker, New York 1993. p.193.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100:2810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101:2598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler WB, Williams M, Matthews WJ Jr, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr 1984; 104:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997; 94:12088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A 2002; 99:6907.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6368 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888700" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12606185" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14555458" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pathophysiology and management of pulmonary infections in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1375392" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cystic fibrosis: molecular biology and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7693108" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular biology of cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2475911" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2570460" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Identification of the cystic fibrosis gene: genetic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2772657" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Identification of the cystic fibrosis gene: chromosome walking and jumping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1371239" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15447951" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Macromolecular interactions and ion transport in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7533790" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7543698" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : CFTR as a cAMP-dependent regulator of sodium channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7719338" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1718606" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nucleoside triphosphates are required to open the CFTR chloride channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1712985" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of deleting the R domain on CFTR-generated chloride channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10872417" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Genotype-phenotype relationships in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8166795" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Correlation between genotype and phenotype in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994263" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Genotype-phenotype correlation for pulmonary function in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767731" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176679" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23974870" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24429096" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1384328" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15371902" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880796" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25404111" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cystic fibrosis genetics: from molecular understanding to clinical application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092437" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31680043" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : CFTR processing, trafficking and interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31680043" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : CFTR processing, trafficking and interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14534332" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14534332" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23149927" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Longitudinal cystic fibrosis care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9016472" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Genotype-phenotype correlations in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11180668" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18292811" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Complex two-gene modulation of lung disease severity in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16207846" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Genetic modifiers of lung disease in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10449435" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398304" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14534402" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Nonclassic cystic fibrosis and CFTR-related diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399953" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lung disease in mice with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9563748" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15790988" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14762183" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association of cystic fibrosis with abnormalities in fatty acid metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14738247" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : New concepts of the pathogenesis of cystic fibrosis lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10567263" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8612275" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17998363" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sodium channels and cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10089875" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cystic fibrosis and the salt controversy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22481418" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cystic fibrosis: a mucosal immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757703" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Inhibition of airway proteases in cystic fibrosis lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757703" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Inhibition of airway proteases in cystic fibrosis lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9351622" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lower airway inflammation in infants and young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9389746" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9616231" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17467552" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Inflammation and anti-inflammatory therapies for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6716217" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827991" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8539601" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9342367" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11997458" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
